adamantane has been researched along with Liver Steatosis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chmelik, M; Harreiter, J; Kautzky-Willer, A; Kosi-Trebotic, L; Thomas, A; Trattnig, S | 1 |
| Araki, E; Goto, R; Igata, M; Kawasaki, S; Kawashima, J; Kitano, S; Kondo, T; Matsumura, T; Matsuyama, R; Miyagawa, K; Motoshima, H; Ono, K | 1 |
| Al-Mrabeh, A; Foley, JE; Hollingsworth, KG; Macauley, M; Schweizer, A; Smith, FE; Taylor, R; Thelwall, PE | 1 |
| Aerts, JM; Aten, J; Bijl, N; Boot, RG; Claessen, N; Groen, AK; Langeveld, M; Moerland, PD; Ottenhoff, R; Sokolović, M; van Eijk, M; van Roomen, CP; Vrins, C | 1 |
| Chung, CC; Ellsworth, KP; Karanam, BV; Lassman, ME; Lee, SH; Li, C; Miller, C; Myers, RW; Powles, M; Salituro, G; Singh, SB; Tota, MR; Wang, J; Wu, M; Zhang, BB | 1 |
| Aerts, JM; Aten, J; Bietrix, FM; Bijl, N; Boot, RG; Dekker, N; Groen, AK; Groener, J; Langeveld, M; Lombardo, E; Ottenhoff, R; Overkleeft, HS; Serlie, M; van Eijk, M; van Roomen, C; Wennekes, T | 1 |
| Aerts, JM; Aten, J; Bietrix, F; Groen, AK; Kuiper, J; Lombardo, E; Ottenhoff, R; Overkleeft, HS; van Eijk, M; van Puijvelde, GH; van Roomen, CP; Verhoeven, AJ | 1 |
1 review(s) available for adamantane and Liver Steatosis
| Article | Year |
|---|---|
Glycosphingolipids and insulin resistance.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Fatty Acids; Fatty Liver; Gaucher Disease; Glucosyltransferases; Glycosphingolipids; Humans; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Pyrrolidines; Receptor, Insulin; Signal Transduction | 2011 |
1 trial(s) available for adamantane and Liver Steatosis
| Article | Year |
|---|---|
Effect of vildagliptin on hepatic steatosis.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Fatty Liver; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Triglycerides; Vildagliptin | 2015 |
5 other study(ies) available for adamantane and Liver Steatosis
| Article | Year |
|---|---|
Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients.
Topics: Adamantane; Adipose Tissue; Adult; Aged; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin | 2017 |
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Topics: Adamantane; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Homeodomain Proteins; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Phlorhizin; Pyrrolidines; Tetrazoles; Trans-Activators; Valine; Valsartan; Vildagliptin | 2013 |
Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Disease Models, Animal; Fatty Liver; Glucose; Glycosphingolipids; Homeostasis; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Triglycerides | 2009 |
Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes.
Topics: Adamantane; Aminobenzoates; Anilides; Animals; Anti-Infective Agents; Diabetes Mellitus; Disease Models, Animal; Fatty Acid Synthases; Fatty Acids; Fatty Liver; Glucose; Humans; Hypoglycemic Agents; Liver; Mice; Mice, Mutant Strains; Oxidation-Reduction; Sterols | 2011 |
Correction of liver steatosis by a hydrophobic iminosugar modulating glycosphingolipids metabolism.
Topics: 1-Deoxynojirimycin; Actins; Adamantane; Animals; Apolipoprotein E3; Cell Membrane; Diet, High-Fat; Dose-Response Relationship, Drug; Fatty Acids; Fatty Liver; Female; Gene Expression; Glycosphingolipids; Humans; Hydrophobic and Hydrophilic Interactions; Imino Sugars; Immunohistochemistry; Insulin; Lipid Metabolism; Liver; Mice; Mice, Knockout; Mice, Transgenic; Muscle, Smooth; Oxidation-Reduction; Receptors, LDL | 2012 |